Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Endo Tool · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| A | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Endo Tool | DEVICE | Computer tool to help achieve glucose control |
Inclusion Criteria: * 18 years or older * military or civilian burns on continuous insulin infusion for 7 days Exclusion Criteria: * not expected to receive insulin for 7 days * less than 18 years old * enrolled in the Continuous Glucose monitoring Study
Endo Tool is an investigational drug being studied for use in burns. It is being evaluated in the context of glycemic control, specifically for patients with burns and hypoglycemia. The drug is currently in Phase 1 clinical development and is not yet approved for any use.
Endo Tool is being developed by United Therapeutics Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker symbol UTHR. The company is conducting clinical research on this investigational drug for the treatment of burns.
Endo Tool is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied in an early-stage clinical trial to evaluate its safety and potential efficacy in patients with burns.
Endo Tool has one completed clinical trial registered under NCT00589589, titled "Computer Decision Support to Achieve Glycemic Control in the ICU." This Phase 1 study enrolled 24 participants with burns and hypoglycemia in the United States. The trial was active-controlled and randomized, though not double-blinded.
No alternative names for Endo Tool have been reported. The drug is identified solely by its name Endo Tool in clinical development records. It is being investigated by United Therapeutics Corporation for its potential role in managing glycemic control in burn patients.